Table 1. Summary of two studies on clinical and cell line CA status across cancer types.
| Cancer type | Clinical data [8] | Cell line data [10] | ||||
|---|---|---|---|---|---|---|
| % of samples with CA | Studies | Total n | % of cell lines that displayed CA (number from total tested in NCI-60 panel) | Range of % of cells showing amplification within cell lines displaying CA | ||
| Solid tumours | ||||||
| Breast | 75–100 | 18 | 582 | 67 | (4 out of 6) | 14.5–32.6 |
| Neural | 89–100 | 7 | 181 | 33 | (2 out of 6) | 22.2–23.6 |
| Ovarian | 78–100 | 3 | 91 | 50 | (3 out of 6) | 14.8–20.0 |
| Head and neck | 62–100 | 8 | 193 | / | / | / |
| Urothelial | 50–100 | 9 | 598 | / | / | / |
| Anogenital | 62–100 | 4 | 100 | / | / | / |
| Colorectal | 65–100 | 3 | 132 | 33 | (2 out of 6) | 23.9–57.1 |
| Prostate | 28–94 | 4 | 266 | 50 | (1 out of 2) | 16.1 |
| Lung | 24–100 | 3 | 249 | 50 | (4 out of 8) | 25.0–62.1 |
| Bone and soft tissue | 18–100 | 6 | 165 | / | / | / |
| Adrenal | 100 | 2 | 14 | / | / | / |
| Hepatobiliary | 0–91 | 2 | 110 | / | / | / |
| Testicular | 33–100 | 1 | 36 | / | / | / |
| Pancreatic | 0–85 | 1 | 16 | / | / | / |
| Renal | 25 | 1 | 8 | 29 | (2 out of 7) | 18.9–30.6 |
| Skin | / | / | / | 57 | (4 out of 7) | 13.7–40.4 |
| Haematological malignancies | ||||||
| Leukaemia | 88–100 | 7 | 266 | 100 | (4 out of 4) | 19.4–48.2 |
| Lymphomas | 41–100 | 10 | 195 | 100 | (1 out of 1) | 14.3 |
| Myeloma | 17–100 | 3 | 161 | 100 | (1 out of 1) | 26.3 |
The clinical data summarises some of the key data from Chan [8], a wide-ranging clinical assessment of CA prevalence. The cell line data summarises key findings from Marteil et al. [10] that assessed CA status across the NCI-60 cell panel. In this study, CA was defined as >13% of cells with >4 centrioles, the cut off being determined by analysis of the frequency and variance of CA in tissue-matched non-cancerous cell lines.